The Center for Genomic Integrity of the Institute of Basic Science (IBS-CGI) at UNIST in Ulsan, South Korea invites applications for Postdocs, Graduate Students and Research Assistants interested in DNA Repair and Damage Signaling, Cancer, Chemical and Chromosome Biology, C. elegans and Bioinformatics.
With UNIST (https://www.unist.ac.kr/) aiming to be among the top Science Universities in the world and IBS (https://www.ibs.re.kr/eng.do) having provided a transformative boost to basic research in Korea, we offer a top-notch research environment. The IBS-CGI has access to most generous core support and aims to become an internationally leading research center for genome maintenance. The UNIST campus is beautifully located in the outskirts of Ulsan, a city of ~ one million, with excellent connections to all of South Korea by high-speed train. The working language at IBS-CGI is English. Opportunities are available at all three branches of IBS-CGI, described below. Candidates with a recent MS or Ph.D. are particularly invited to apply.
Molecular and Cellular Biology Branch (MCBB), directed by Kyungjae Myung
Research in our laboratory focuses on the identification of novel mechanisms of DNA replication, repair and recombination as well as the DNA damage response and translate these for developing new cancer therapies. We work on 1. Regulatory mechanisms of DNA replication forks (Nat Commun, 2019, 10, 5718), (Nat Commun, 2019, 10, 2420); 2. DNA double strand break repair (EMBO Rep, 2020, 21 e48676); 3. Animal models with DNA repair defects (Nat Cell Biol, 2020, 22, 1411); and 4. Translational approaches to target DNA repair pathways (PNAS, 2022, 119, e2103532119). We are looking for researchers with expertise in molecular and cell biology, biochemistry, chemical biology or mouse models.
Chemical & Cancer Biology Branch (CCBB), directed by Orlando D. Schärer
Research in our laboratory is aimed at elucidating mechanisms of various DNA repair pathways and to study their connection to carcinogenesis and anti-tumor therapy. A main current focus is on understanding how DNA adducts formed by a number of antitumor agents are processed in human cells and how we can leverage this knowledge to improve outcomes in cancer therapy. We are looking for biochemists, molecular/cell biologists for our mechanistic studies of the NER and ICL repair pathways (bioRvix, 2022), (NAR, 2020, 48, 2173) and for organic and bioanalytical chemists to develop new tools and approaches to study DNA repair pathways (Chem Res Tox, 2021, 34, 1790), (NAR, 2020, 48, 8461).
Genetic and Genomic Toxicology Branch (GGTB) directed by Anton Gartner
One of the major goals of our research is to understand the origin of mutational signatures observed in cancers. We are determining mutational signatures in an isogenic set of human cell lines deficient in DNA repair pathways and exposed to chemotherapeutic agents. The ultimate goal is to understand the development of cancers and to find the “weak” spots in cancer genomes to target for therapy. We are building on our previous experience in the analysis of C. elegans genomes (Nat. Commun, 2020, 11, 2169). In addition to whole genome sequencing, we employ a wide range of biochemical and cytological techniques to investigate the molecular mechanisms of tumor chemotherapy resistance. We are looking for researchers with expertise in molecular and cell biology, data analysis and bioinformatics. Finally, we are also looking for researchers interested in C. elegans apoptosis, damage signaling and genome stability.
How to apply: Candidates should submit a letter of interest, curriculum vitae, and the names of three references in a single pdf file via the APPLY button by June 12, 2022. Please feel free to directly contact Profs. Myung, Schärer or Gartner by E-mail for further information.